(Q39539865)

12 September 2017

Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587. (English)

1 reference

12 September 2017

Weigang Wen

1

1 reference

12 September 2017

Lijie Zhang

2

1 reference

12 September 2017

Jirun Peng

3

1 reference

12 September 2017

Juanjuan Chen

4

1 reference

12 September 2017

Jiaqing Hao

5

1 reference

12 September 2017

Xiaofeng Li

6

1 reference

12 September 2017

Xiaoping Qian

7

1 reference

12 September 2017

Pumei Zeng

8

1 reference

12 September 2017

Yu Zhang

9

1 reference

12 September 2017

Yanhui Yin

10

1 reference

12 September 2017

27 June 2011

1 reference

12 September 2017

1 reference

12 September 2017

102

1 reference

12 September 2017

1455-1461

1 reference

12 September 2017

8

1 reference

Immunity against cancer: lessons learned from melanoma.

12 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Design and development of synthetic peptide vaccines: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Multiple roles for CD4+ T cells in anti-tumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Peptide epitope identification for tumor-reactive CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Cancer/testis (CT) antigens: potential targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01986.X

10.1111/J.1349-7006.2011.01986.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference